ResearcherTUM KlinikumActive in the last 2 years
Christoph Schlag
Matched on ORCID iD 0000-0003-3227-2724; OpenAlex author ID A5044031267. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 49
2020: 1 paper · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper
Papers 4
- Comparison of endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy to generate pancreatic cancer organoids: Randomized trial. Last author DOI 10.1055/a-2257-3171↗
- Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
- Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
- Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
Closest collaborators
The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Felix Orben · 4 shared papers, 2020–2024 · strength 0.47
- Paper Comparison of endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy to generate pancreatic cancer … DOI 10.1055/a-2257-3171↗
- Paper Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. DOI 10.15252/emmm.202114876↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Maximilian Reichert · 4 shared papers, 2020–2024 · strength 0.47
- Paper Comparison of endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy to generate pancreatic cancer … DOI 10.1055/a-2257-3171↗
- Paper Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. DOI 10.15252/emmm.202114876↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Roland Michael Schmid · 4 shared papers, 2020–2024 · strength 0.47
- Paper Comparison of endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy to generate pancreatic cancer … DOI 10.1055/a-2257-3171↗
- Paper Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. DOI 10.15252/emmm.202114876↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Günter Schneider · 4 shared papers, 2020–2024 · strength 0.47
- Paper Comparison of endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy to generate pancreatic cancer … DOI 10.1055/a-2257-3171↗
- Paper Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. DOI 10.15252/emmm.202114876↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Roland Rad · 3 shared papers, 2020–2022 · strength 0.29
- Paper Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. DOI 10.15252/emmm.202114876↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Paper Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. DOI 10.1172/jci.insight.137809↗
- Dieter Saur · 3 shared papers, 2020–2022 · strength 0.29
- Paper Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. DOI 10.15252/emmm.202114876↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Paper Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. DOI 10.1172/jci.insight.137809↗
- Alexander Herner · 2 shared papers, 2020–2024 · strength 0.25
- Guido von Figura · 2 shared papers, 2020–2024 · strength 0.25
- Bo Kong · 2 shared papers, 2022 · strength 0.22
- Johannes Roman Wiessner · 1 shared paper, 2024 · strength 0.18
- Katja Peschke · 2 shared papers, 2020–2022 · strength 0.18
- Wilko Weichert · 2 shared papers, 2020–2022 · strength 0.18
- Sebastian Lange · 2 shared papers, 2020–2022 · strength 0.18
- Rickmer Braren · 2 shared papers, 2020–2022 · strength 0.18
- Matthias Wirth · 2 shared papers, 2020–2022 · strength 0.18
- Anna Melissa Schlitter · 1 shared paper, 2022 · strength 0.11
- H. Carlo Maurer · 1 shared paper, 2022 · strength 0.11
- Felix N. Harder · 1 shared paper, 2022 · strength 0.11
- Helmut Friess · 1 shared paper, 2022 · strength 0.11
- İhsan Ekin Demir · 1 shared paper, 2022 · strength 0.11
- Katharina Lankes · 1 shared paper, 2022 · strength 0.11
- Christian Schneeweis · 1 shared paper, 2022 · strength 0.11
- Yonggan Xue · 1 shared paper, 2022 · strength 0.11
- Zonera Hassan · 1 shared paper, 2022 · strength 0.11
- Bernhard Küster · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.